Interview, Fireside Chat
Wednesday Lunch feat. Bill Cassidy
- Addresses the treatment gap affecting fewer than 500 of nearly 10,000 global diseases, noting that reliance on future medical progress is unreliable due to misaligned incentives and capital shortages.
- Anticipates an ecosystem that encourages scientific exploration and affordability while warning that delaying mobilization fosters bureaucratic silos that cost lives.
- Predicts legislative pressure for a drug pricing package if the House submits a reasonable proposal, with expectations of broad Republican support and a 60% probability of passage by December 31st.
- Projects that the Cassidy-Hasson STOP Act could save $17 billion while respecting the ecosystem, contrasting this with the risk that government mandates capping rates at 65–95% of gross receipts would drive away innovation and venture capital.
- Forecasts that federal monopsony purchasing power could temporarily lower prices but ultimately reduce innovation, potentially causing commercial prices to rise and private equity to withhold investment in drugs where the government captures up to 95% of value.
- Warns of adverse market outcomes including doctors abandoning essential procedures like childbirth for higher-margin services, rural hospital closures due to rate mandates, and investors abandoning fruitless endeavors like Alzheimer's drug development.
- Highlights that regulatory rules intended to foster competition are currently being arbitraged to artificially inflate costs, a trend described as short-sighted and harmful to market viability.
- Outlines the economic urgency of early treatment for conditions like sickle cell disease, projecting that a $1.5 million gene therapy administered in the first week of life saves $50 million in long-term costs, whereas treatment at age 45 yields no savings due to irreversible organ damage.
- Notes the potential expansion of "Netflix-style" subscription models for fixed budgets in settings like Medicaid or prisons, while cautioning that scaling expensive therapies like gene treatments to large populations (e.g., 700,000 patients) could cost trillions in the initial one to two years.
- Expects continued political and economic cycles regarding drug costs, predicting that new challenges will emerge requiring further work within 10 years.